Lantheus (LNTH) TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit summary

Company overview and market position

• Leading radiopharmaceutical company with over 65 years of experience in both diagnostic and therapeutic products.

• Strong expertise in just-in-time manufacturing and supply chain for radiopharmaceuticals, exemplified by the success of PYLARIFY.

• Competence in handling a range of isotopes with varying half-lives, supporting both centralized and distributed production.

Isotope strategy and selection

• Isotope strategy role focuses on evaluating clinical effects, half-life, chemistry, and regulatory trends for new products.

• Alpha vs. beta emitters, half-life, and waste handling are key considerations in isotope selection.

• Regulatory compliance and anticipation of future guidelines are integral to isotope choice.

Supply chain and production challenges

• Reliable isotope supply is critical for both diagnostics and therapeutics, with shortages impacting clinical trials.

• Industry must balance current availability with investment in future supply, especially for high-demand isotopes like actinium and lutetium.

• Robust, redundant supply chains and partnerships are essential to mitigate risks from geopolitical or operational disruptions.